切换至 "中华医学电子期刊资源库"

中华腔镜泌尿外科杂志(电子版) ›› 2022, Vol. 16 ›› Issue (02) : 106 -110. doi: 10.3877/cma.j.issn.1674-3253.2022.02.003

临床研究

MRI 3D-LAVA动态增强联合FRFSE序列诊断早期前列腺癌的效能
刘成环1,(), 李俊华1, 祁海峰1, 龚晓萍1   
  1. 1. 810000 青海,西宁市第一人民医院放射科
  • 收稿日期:2020-11-02 出版日期:2022-04-01
  • 通信作者: 刘成环

Diagnosis of early prostate cancer by MRI of 3D-LAVA dynamic enhancement combined with FRFSE sequence

Chenghuan Liu1,(), Junhua Li1, Haifeng Qi1, Xiaoping Gong1   

  1. 1. Department of Radiology, the First People's Hospital of Xining City, Qinghai 810000, China
  • Received:2020-11-02 Published:2022-04-01
  • Corresponding author: Chenghuan Liu
引用本文:

刘成环, 李俊华, 祁海峰, 龚晓萍. MRI 3D-LAVA动态增强联合FRFSE序列诊断早期前列腺癌的效能[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2022, 16(02): 106-110.

Chenghuan Liu, Junhua Li, Haifeng Qi, Xiaoping Gong. Diagnosis of early prostate cancer by MRI of 3D-LAVA dynamic enhancement combined with FRFSE sequence[J/OL]. Chinese Journal of Endourology(Electronic Edition), 2022, 16(02): 106-110.

目的

探讨核磁共振成像(MRI)三维容积内插快速扰相梯度回波序列(3D-LAVA)屏气检查动态增强联合快速翻转快速自旋回波序列(FRFSE)对早期前列腺癌的诊断效能。

方法

对我院2013年6月至2019年6月210例可疑早期前列腺癌的临床资料进行回顾,均实施MRI 3D-LAVA动态增强、FRFSE序列扫描。总结两种扫描序列的检查结果,分析不同方法诊断早期前列腺癌的效能;另统计多参数磁共振(mpMRI)的诊断结果,绘制受试者工作特征曲线(ROC)评价不同方法诊断早期前列腺癌的效能。

结果

早期前列腺癌的构成比为38.10%;早期前列腺癌(+)患者峰值和强化率均高于前列腺癌(-)受检者,且早期前列腺癌(+)患者峰值时间短于后者,强化幅度小于后者,差异均有统计学意义(P<0.05);MRI 3D-LAVA动态增强联合FRFSE序列诊断早期前列腺癌的灵敏度与MRI 3D-LAVA动态增强、FRFSE序列单独诊断相近,特异度、准确度和曲线下面积(AUC)均高于单独诊断;MRI 3D-LAVA动态增强联合FRFSE序列诊断早期前列腺癌的灵敏度、特异度、准确度均与mpMRI相当,且二者AUC对比差异无统计学意义(P>0.05)。

结论

在早期前列腺癌诊断中MRI 3D-LAVA动态增强、FRFSE序列扫描联合检查的效能理想,与病理结果的一致性良好,和mpMRI诊断早期前列腺癌的效能相近。

Objective

To explore the diagnostic efficacy of three-dimensional MRI GRE sequence (3D-LAVA) gas-screen examination and fast recovery fast spin echo sequence (FRFSE) in early prostate cancer by magnetic resonance imaging (MRI).

Methods

The clinical data of 210 suspected cases of early prostate cancer in our hospital from June 2013 to June 2019 were reviewed. MRI 3D-LAVA and FRFSE sequence scanning were performed in all cases. The results of two scanning sequences were summarized and the efficacy of different methods in the diagnosis of early prostate cancer was analyzed. In addition, the diagnosis results of multi-parameter magnetic resonance imaging (mpMRI) were compared, and the receiver operating characteristic curve (ROC) was drawn to evaluate the efficacy of different methods in the diagnosis of early prostate cancer.

Results

The ratio of early prostate cancer was 38.10%. The peak value and enhancement rate of early prostate cancer (+) patients were higher than those of prostate cancer (-) patients, and the peak time of early prostate cancer (+) patients was shorter than that of the latter, and the enhancement extent was smaller than that of the latter, the difference was statistically significant (P<0.05). The sensitivity of MRI 3D-LAVA dynamic enhancement combined with FRFSE sequence in the diagnosis of early prostate cancer was similar of MRI 3D-LAVA dynamic enhancement and FRFSE sequence alone, and the specificity, accuracy and AUC were higher than those of single diagnosis. The sensitivity, specificity and accuracy of 3D-LAVA dynamic contrast-enhanced MRI combined with FRFSE sequence in the diagnosis of early prostate cancer were comparable of mpMRI, and there was no significant difference in AUC between the two groups (P>0.05).

Conclusion

In the diagnosis of early prostate cancer, the efficiency of combination of 3D-LAVA dynamic enhancement and FRFSE sequence scanning is effective, which is in good agreement with pathological results, and is similar of mpMRI in the diagnosis of early prostate cancer.

图1 病例入组流程图
表1 不同MRI序列扫描检查的诊断结果(例)
表2 不同早期前列腺癌发生情况MRI 3D-LAVA动态增强SI-T曲线参数对比(±s)
图2 不同方法诊断早期前列腺癌的ROC曲线
图4 一例早期前列腺癌患者的MRI
表3 不同方法诊断早期前列腺癌的效能分析(%)
[1]
兰蓝, 赵飞, 蔡玥, 等. 中国居民2015年恶性肿瘤死亡率流行病学特征分析[J]. 中华流行病学杂志, 2018, 39(1): 32-34.
[2]
Koo KC, Lee JS, Kim JW, et al. Impact of clinical trial participation on survival in patients with castration-resistant prostate cancer: a multi-center analysis [J]. BMC Cancer, 2018, 18(1): 468.
[3]
Salembier C, Villeirs G, De Bari B, et al. ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer [J]. Radiother Oncol, 2018, 127(1): 49-61.
[4]
Manfredi M, Mele F, Garrou D, et al. Multiparametric prostate MRI: technical conduct, standardized report and clinical use [J]. Minerva Urol Nefrol, 2018, 70(1): 9-21.
[5]
Brown LC, Ahmed HU, Faria R, et al. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study [J]. Health Technol Assess, 2018, 22(39): 1-176.
[6]
Coker MA, Glaser ZA, Gordetsky JB, et al. Targets missed: predictors of MRI-targeted biopsy failing to accurately localize prostate cancer found on systematic biopsy [J]. Prostate Cancer Prostatic Dis, 2018, 21(4): 549-555.
[7]
张凯, 张志鹏, 朱刚, 等. 两种核磁靶向穿刺诊断有临床意义前列腺癌精确性的比较[J]. 中华腔镜泌尿外科杂志(电子版), 2019, 13(5): 293-296.
[8]
王慧慧, 何群, 沈棋, 等. 多参数MRI对前列腺癌包膜侵犯的诊断价值[J]. 实用放射学杂志, 2018, 34(4): 556-559.
[9]
Sherrer RL, Lai WS, Thomas JV, et al. Incidental findings on multiparametric MRI performed for evaluation of prostate cancer [J]. Abdom Radiol (NY), 2018, 43(3): 696-701.
[10]
Yarlagadda VK, Lai WS, Gordetsky JB, et al. MRI/US fusion-guided prostate biopsy allows for equivalent cancer detection with significantly fewer needle cores in biopsy-naive men [J]. Diagn Interv Radiol, 2018, 24(3): 115-120.
[11]
Kim JG, Kim CK, Kim JH. Prebiopsy multiparametric mri with cancer-negative findings in men with suspected prostate cancer: evaluation using prostate imaging reporting and data system version 2 [J]. AJR Am J Roentgenol, 2018, 211(1): 121-126.
[12]
Li P, You S, Nguyen C, et al. Genes involved in prostate cancer progression determine MRI visibility [J]. Theranostics, 2018, 8(7): 1752-1765.
[13]
冼土增, 张俊夫, 罗飞, 等. 多参数磁共振成像联合四基因模型提高前列腺癌早期诊断效能的临床研究[J]. 中华腔镜泌尿外科杂志(电子版), 2018, 12(3): 11-15.
[1] 杨倩, 李秋洋, 李楠, 罗渝昆, 唐杰. 基于超声纹理影像转录组学预测前列腺癌[J/OL]. 中华医学超声杂志(电子版), 2024, 21(03): 319-326.
[2] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[3] 祝炜安, 林华慧, 吴建杰, 黄炯煅, 吴婷婷, 赖文杰. RDM1通过CDK4促进前列腺癌细胞进展的研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 618-625.
[4] 王功炜, 李书豪, 魏松, 吕博然, 胡成. 溶瘤病毒M1对不同前列腺癌细胞杀伤效果的研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 626-632.
[5] 施一辉, 张平新, 朱勇, 杨德林. 机器人辅助前列腺根治术后切缘阳性的研究进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 633-637.
[6] 李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[7] 胡思平, 熊性宇, 徐航, 杨璐. 衰老相关分泌表型因子在前列腺癌发生发展中的作用机制[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 425-434.
[8] 杨勇军, 曾一鸣, 贺显雅, 卢强, 李远伟. ASA分级≥Ⅲ级患者局麻经会阴前列腺多模态影像融合穿刺的安全性和有效性[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 441-447.
[9] 李鑫钊, 张廷涛, 朱峰, 刘金山, 刘大闯. 血纤维蛋白原、D-二聚体及碱性磷酸酶诊断前列腺癌骨转移的价值分析[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 459-463.
[10] 刘中文, 刘畅, 高洋, 刘东, 林世庆, 杨建华, 赵福义. 尿液microRNA-326与腹腔镜根治性膀胱切除术治疗膀胱癌患者预后的相关性研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(04): 386-391.
[11] 杨龙雨禾, 王跃强, 招云亮, 金溪, 卫娜, 杨智明, 张贵福. 人工智能辅助临床决策在泌尿系肿瘤的应用进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(02): 178-182.
[12] 张铭星, 刘文倩, 王以然, 赵泽恬, 袁欣怡, 丁留成. 江苏地区腹腔镜下前列腺癌根治术后一年夜尿症发生率及相关危险因素多中心回顾性研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(02): 141-145.
[13] 李俊涛, 张天佑, 叶雷, 郭强, 吴坚坚, 尧冰, 王德娟, 邱剑光. 保留"尿道系膜"的腹腔镜下前列腺根治性切除术后尿控情况的研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(01): 19-24.
[14] 陈钊, 钟克力, 江志鹏, 傅宇翔, 范宝航, 吴文飞. 前列腺癌术后腹股沟疝的发生率及危险因素分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(04): 396-401.
[15] 吕泉龙, 史文杰, 孙文国. 免疫检查点抑制剂在治疗转移性去势抵抗性前列腺癌中的研究进展[J/OL]. 中华诊断学电子杂志, 2024, 12(01): 69-72.
阅读次数
全文


摘要